Literature DB >> 30939587

Suppressive Effect of Everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: Implications for the Successful Minimization of Calcineurin Inhibitor Use in Transplantation.

Kenta Iwasaki1, Nana Kitahata1, Yuko Miwa1, Kazuharu Uchida1, Yutaka Matsuoka2, Kosei Horimi2, Takaaki Kobayashi2.   

Abstract

BACKGROUND: Success with calcineurin inhibitors (CNIs) such as cyclosporine A (CSA) and tacrolimus (TAC) in organ transplantation has demonstrated that cytokine suppression is a key factor in patient management. However, the exact effects of recently introduced immunosuppressive agents other than CNI on cytokine expression remain unknown. In this study, the action of the mTOR-inhibitor everolimus (EVR) and that of the antimetabolite mycophenolic acid (MPA) on the transcription of several cytokines was investigated.
METHODS: Peripheral blood mononuclear cells obtained from healthy volunteers were stimulated with anti-CD3/28 microbeads in the presence of CSA, TAC, EVR, and/or MPA for 8 hours. The mRNA levels of each cytokine were measured using quantitative real-time polymerase chain reaction.
RESULTS: MPA had no inhibitory effect on any of the cytokines tested. EVR showed moderate inhibition of IL-2, IL-10, IL-21, and IFNγ levels. These cytokines were further analyzed to investigate the additive effect of EVR in combination with CNI. The beneficial effect of EVR addition was seen at low concentrations of CSA or TAC, while no additive effect was observed at high concentrations.
CONCLUSIONS: EVR might effectively inhibit the activation of recipient immune cells in combination with a low dose of CNI, maximizing clinical benefit by preventing graft rejection and alleviating CNI-induced adverse effects.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30939587     DOI: 10.1097/FTD.0000000000000630

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  2 in total

Review 1.  Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients.

Authors:  Nuri Baris Hasbal; Didem Turgut; Ebru Gok Oguz; Sena Ulu; Ozkan Gungor
Journal:  Ann Transplant       Date:  2021-03-12       Impact factor: 1.530

2.  Dose-Dependent Acute Effects of Everolimus Administration on Immunological, Neuroendocrine and Psychological Parameters in Healthy Men.

Authors:  Tina Hörbelt; Anna Lena Kahl; Frederike Kolbe; Susann Hetze; Benjamin Wilde; Oliver Witzke; Manfred Schedlowski
Journal:  Clin Transl Sci       Date:  2020-05-31       Impact factor: 4.689

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.